Lp(a) Drug Class Shaken as Pelacarsen Trial Fails

undefined

Pelacarsen reduced Lp(a) biomarker levels as designed yet failed to cut cardiovascular deaths, heart attacks, or strokes in 8,323 high-risk patients.
NVS fell 3.6%, IONS dropped 10%, and AMGN lost 5% as contagion fear spread across the entire Lp(a)-lowering drug class.
Amgen's olpasiran and Eli Lilly's lepodisiran remain in active Phase 3 trials with combined enrollment exceeding 19,000 patients and outcomes data still pending.

Novartis's pelacarsen missed the primary endpoint in the 8,323-patient Lp(a)HORIZON trial Sept. 7, raising the unsettling question of whether lowering lipoprotein(a) prevents cardiovascular events at all.

Lead

Novartis (NVS) and Ionis Pharmaceuticals (IONS) disclosed on the morning of September 7, 2026 that pelacarsen - their jointly developed cardiovascular drug - failed to reduce major adverse cardiovascular events in the pivotal Phase 3 Lp(a)HORIZON trial, despite biochemically suppressing lipoprotein(a) concentrations across an 8,323-patient study population with elevated Lp(a) and established cardiovascular disease. The outcome eliminated what had been estimated as a peak annual revenue opportunity approaching $6 billion and confronted cardiovascular medicine with a foundational scientific paradox: a drug that does exactly what it was designed to do, yet leaves clinical outcomes unchanged.

What Did the Trial Show?

Lp(a)HORIZON enrolled 8,323 patients and tracked a composite primary endpoint covering cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization. Pelacarsen, an antisense medicine engineered to suppress apolipoprotein(a) production in the liver, achieved the biochemical reduction it was designed to deliver - Lp(a) levels fell as expected. The composite event rate, however, did not separate meaningfully from placebo.

The dissociation between biomarker reduction and clinical outcome is the trial's defining problem. Lipoprotein(a) - a genetically determined low-density lipoprotein variant that affects roughly one in five Americans and is largely resistant to diet, exercise, or existing lipid-lowering therapies - has been widely treated as a causal cardiovascular risk factor, not merely a correlate. The Lp(a)HORIZON result does not disprove that causal link, but it removes the strongest clinical evidence the field had anticipated in its support.

Why Did NVS, IONS, and AMGN Sell Off So Sharply?

The selloff was immediate, broad, and calibrated to each company's exposure. Novartis (NVS), which licensed pelacarsen from Ionis in 2019 for worldwide development, declined 3.6% as the asset's commercial value effectively reset to zero. Ionis (IONS), which retains royalty interests and milestone-linked economics tied to the program, absorbed the steeper hit - shares fell 10%, reflecting the elimination of a near-term revenue catalyst that had been embedded in the stock's valuation.

Amgen (AMGN) declined 5% despite having no direct pelacarsen exposure. The move was a class-risk trade: if a drug that successfully lowered Lp(a) could not prevent heart attacks in 8,323 patients, the mechanism underlying all Lp(a)-lowering drugs - olpasiran included - faces a credibility burden it has not previously carried. Investors priced that uncertainty into AMGN shares before OCEAN(a) data exist to address it.

What Does This Mean for Olpasiran and Eli Lilly's Program?

Amgen's olpasiran, a small-interfering RNA therapy that demonstrated Lp(a) reductions approaching 94% in Phase 2 studies, is enrolled in the OCEAN(a) Phase 3 cardiovascular outcomes trial with more than 7,200 patients and a primary completion date in December 2026. Eli Lilly (LLY) is running the ACCLAIM-Lp(a) trial for lepodisiran, enrolling 12,500 patients across established ASCVD and high-risk primary prevention populations, with completion targeted for 2029.

Both programs will advance arguments based on biochemical distinctions: siRNA versus antisense mechanism, dosing frequency, depth of suppression relative to pelacarsen's achieved reduction, and patient population selection. Investigators will note that olpasiran's near-complete suppression may represent a materially different biological intervention than pelacarsen's. That hypothesis, however, now requires clinical proof that did not exist on September 7.

The Lp(a)HORIZON failure shifts the burden of proof squarely onto the remaining trials. Every interim analysis and data readout for OCEAN(a) and ACCLAIM-Lp(a) now carries elevated market sensitivity. The biotech sector, already navigating a compressed environment for late-stage cardiovascular programs, must now absorb the possibility that the entire Lp(a) drug class was built on a causal assumption that Phase 3 evidence has not confirmed.

Outlook

Pelacarsen's failure in Lp(a)HORIZON represents the most consequential setback the emerging Lp(a)-lowering drug class has faced. Novartis and Ionis will assess whether further development is scientifically or commercially justified. The class itself will not be vindicated or condemned until OCEAN(a) and ACCLAIM-Lp(a) report their primary endpoints - results that arrive between late 2026 and 2029. Until then, elevated scientific uncertainty is the defining characteristic of the Lp(a) drug category, and the market has priced accordingly.

Mentioned tickers: NVS, IONS, AMGN, LLY